You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華(09969.HK)降解劑產品ICP-490新藥研究申請獲國家藥監局受理
阿思達克 04-29 11:10
諾誠健華(09969.HK)公佈,公司自主研發的新型靶向蛋白降解劑ICP-490新藥研究(IND)申請獲國家藥品監督管理局受理。 ICP-490爲公司自主研發的創新藥,源自公司的分子膠平臺,ICP-490將開發用於治療復發/難治多發性骨髓瘤(MM),以及包括瀰漫大B細胞淋巴瘤(DLBCL)在內的非霍奇金淋巴瘤(NHL)等血液腫瘤疾病。 諾誠健華聯合創始人、董事長兼CEO崔霽鬆表示,ICP-490進一步增強公司在血液瘤領域的產品管線,未來將努力推進ICP-490的臨牀開發。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account